A phase II trial of savolitinib, a MET inhibitor, found that the drug induced partial responses in some patients with papillary renal cell carcinoma and was well tolerated, prompting drug makers Chi-Med and AstraZeneca to launch a phase III study.
http://ift.tt/2eJMTBo
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου